(571) 447-5500

EAS Blog

EAS Independent Consultants and staff provide in-depth regulatory expertise and authoritative reporting on a variety of compliance requirements for industries that EAS serves. Our experts break down complicated topics into easily understandable summaries and analysis. Subscribe to our newsletter and receive these monthly updates directly in your in-box.

Responding to Food and Seafood FDA 483s

Responding to Food and Seafood FDA 483s

Presented by Mark Moen and Jeb HunterMay 19, 2026 | 2:00 PM ETWhen the FDA issues a Form 483 or Warning Letter, your response is critical—and time-sensitive. How you respond can directly impact regulatory outcomes, enforcement risk, and your firm’s credibility. This webinar will walk through FDA...

read more
FDA Announces New Steps to Streamline Biosimilar Development

FDA Announces New Steps to Streamline Biosimilar Development

FDA Takes Additional Steps to Support Biosimilar Development The U.S. Food and Drug Administration has announced new actions aimed at streamlining the development of biosimilar medicines and improving access to lower-cost biologic therapies. Biosimilars are biological products that are highly...

read more
FDA Finalizes Rule Standardizing National Drug Code Format

FDA Finalizes Rule Standardizing National Drug Code Format

FDA Final Rule Revises National Drug Code Format and Barcode Requirements FDA has issued a final rule revising the format of the National Drug Code (NDC) and updating certain drug label barcode requirements. The National Drug Code is a unique identifier assigned to drug products marketed in the...

read more
EAS Expands Services: Biologics and Biosimilars Consulting

EAS Expands Services: Biologics and Biosimilars Consulting

EAS Consulting Group is pleased to announce the expansion of our service offerings to include Biologics and Biosimilars regulatory and quality consulting. As these products continue to play an increasingly important role in the life sciences industry, organizations face complex challenges related...

read more
Drug and Device Corner 2026 February

Drug and Device Corner 2026 February

Reminder that per the CARES Act of 2020, drug establishments are required to report NDC volumes annually. 2025 reports are due no later than 31 March 2026. Reminder that the agency began their policy enforcement late in 2025 contacting facilities that had not reported all NDC volumes. If you have...

read more
Dietary Supplement Finished Product Testing and Specifications

Dietary Supplement Finished Product Testing and Specifications

Presented by Shelly BlackwellThursday, April 16, 2026 | 3:00 PM ETThe FDA requires that dietary supplement manufactures establish finished product specifications and test to ensure the specifications are met. However, the process of implementing this requirement is not always straightforward. What...

read more
FDA Initiates Review of BHA, a Common Food Preservative

FDA Initiates Review of BHA, a Common Food Preservative

The U.S. Food and Drug Administration has announced that it is launching a safety assessment of butylated hydroxyanisole (BHA), a synthetic antioxidant widely used in food products to prevent rancidity in fats and oils. BHA has been authorized for use in food for decades within established...

read more
Building Food Safety Culture When No One Is Watching

Building Food Safety Culture When No One Is Watching

What does food safety look like when no one is watching? In this Issue of the Month, EAS Independent Consultant Sebnem Karasu explores how real food safety culture is built, sustained, and revealed under pressure, and why systems, not slogans, make the difference.

read more
Drug and Device Corner 2026 January

Drug and Device Corner 2026 January

Reminder that per the CARES Act of 2020, drug establishments are required to report NDC volumes annually. This applies to all facilities that manufacture, prepare, propagate, compound, or process drugs for commercial distribution in the United States. 2025 reports are due no later than 31 March...

read more
Amazon Tightens GMP / cGMP Requirements for Dietary Supplements

Amazon Tightens GMP / cGMP Requirements for Dietary Supplements

Amazon has expanded its compliance requirements for dietary supplements sold on its marketplace. Effective now, all dietary supplement products must demonstrate current Good Manufacturing Practice (cGMP) compliance verified by an accredited third-party Testing, Inspection, and Certification (TIC) organization. This is an expansion of previous testing requirements that had initially applied only to certain high-risk categories (e.g., sexual enhancement, weight management, sports nutrition).

read more
Artificial Intelligence: Quality Friend or Foe

Artificial Intelligence: Quality Friend or Foe

This Issue of the Month explores how artificial intelligence is being applied in regulated industries, examining potential benefits for quality and compliance programs while highlighting risks and considerations companies should evaluate before integrating AI into regulatory operations.

read more
Drug and Device Corner 2025 December

Drug and Device Corner 2025 December

Reminder that if the 31 December registration renewal deadline is missed, drug and medical device facility registrations will drop off the public databases. Registrations can be reactivated with a successful renewal submission. Any NDC drug listings that miss the blanket no change certification...

read more

Subscribe to the EASeNews Newsletter: